NeuroVision Imaging LLC, a Sacramento, CA-based developer of digital imaging and diagnostic solutions for Alzheimer’s disease (AD), raised $5m in Series B financing.
The round was led by Wildcat Capital Management, the family office of TPG co-founder David Bonderman. In conjunction with the funding, Leonard Potter, chief investment officer and president of Wildcat Capital Management, joined NeuroVision’s board of directors.
The company intends to use the funds to advance validation and regulatory approval for its retinal imaging technology in connection with the early detection and monitoring of amyloid pathology related to Alzheimer’s disease.
Led by Steven Verdooner, CEO, NeuroVision develops digital imaging and diagnostic solutions for Alzheimer’s disease (AD). The company’s founding team, under the direction of Keith L. Black, M.D. and Maya Koronyo-Hamaoui, Ph.D. (Cedars-Sinai Medical Center in Los Angeles), has validated noninvasive retinal imaging in transgenic mouse models and human cadaver studies for the early detection of amyloid beta plaque in the retina.
NeuroVision has developed a proprietary test that utilizes a retinal imaging system and a proprietary high-bioavailability curcumin formulation. Commercialization plans include establishment of a simple eye test as a standard of care for noninvasive, high-resolution optical imaging for detection of amyloid beta plaque in AD diagnosis, prognosis assessment and response to therapies.
The company holds the exclusive worldwide license to this technology, which is owned by Cedars-Sinai.